Succinylcholine

The Depolarizing Paralytic

Drug Spotlight · IV Paralytic · Neuromuscular Blocker

TL;DR

Succinylcholine is an ultra-rapid paralytic drug that freezes every skeletal muscle in the body within 60 seconds. It works by flooding the neuromuscular junction to force a massive initial muscle contraction before locking the receptors entirely shut. This makes it the absolute gold standard for emergency intubation because it works incredibly fast and wears off in less than 10 minutes. However, because it has absolutely zero effect on the brain, failing to give a sedative first guarantees the patient will be awake and trapped in a paralyzed body. That horrific scenario, combined with severe cardiovascular and metabolic risks, is why this medication generates major anesthesia malpractice lawsuits.

Identity

Chemical Profile

Chemical Name

Suxamethonium chloride

Formulation

Usually supplied as a clear, water-soluble liquid in a sealed vial. Because the molecules naturally break down at room temperature, it must be refrigerated and discarded after roughly 14 to 30 days once removed from cold storage. Something they taught me in physiology is that its structure is literally just two molecules of acetylcholine (the body’s natural movement signal) glued together!

Key Properties

Highly water-soluble, allowing it to stay in the bloodstream and reach the muscle junction rapidly.
Broken down entirely in the blood by a specific enzyme called pseudocholinesterase, completely bypassing the liver and kidneys.
Causes an immediate efflux of cellular potassium, normally raising serum potassium levels by about 0.5 milliequivalents per liter (mEq/L).

Background

History

Before succinylcholine, surgeons had to rely on natural plant extracts like curare to paralyze patients. Those older drugs took a long time to work and even longer to wear off. The development of a rapid paralytic completely revolutionized emergency medicine and trauma surgery.

1906

Reid Hunt and René de M. Taveau synthesize the molecule. They are studying blood pressure and completely miss its paralyzing effects. At this point, it is merely a laboratory curiosity.
1949

Pharmacologist Daniel Bovet figures out that the chemical effectively blocks nerve transmission, a discovery that later contributes to his Nobel Prize for work on muscle relaxants.
1951

Stephen Thesleff in Sweden and Francis Foldes in the United States successfully test the drug in human surgeries to relax abdominal muscles.
1952

The medical community quickly adopts it for emergency intubation because it paralyzes patients much faster than any prior medication.
1960s to Present

It remains the gold standard for trauma emergencies. However, physicians also realize it is a primary trigger for Malignant Hyperthermia, a rare and deadly genetic reaction.

Pharmacology

How It Works

To understand how this works, we have to look at the gap between the nerve and the muscle, known as the neuromuscular junction (NMJ). When your brain wants to move your arm, the nerve releases a chemical called acetylcholine (ACh) to hit the muscle receptor. Succinylcholine mimics this natural chemical perfectly, but because it is essentially a doubled molecule, it acts like a permanent key jammed in the ignition. It forces a massive initial muscle contraction, which we see clinically as full body muscle twitching called fasciculations. After this initial firing, it refuses to leave the receptor, leaving the muscle completely exhausted and unable to accept new signals. From this we can see that the muscle remains completely paralyzed until the drug eventually diffuses away.

This is why the duration is so impressively reliable. The drug does not rely on the liver or kidneys to wear off. Instead, a specific enzyme in the blood called pseudocholinesterase acts like molecular scissors to cut the drug in half. This process usually clears the paralysis in a highly predictable 5 to 10 minute window.

Dosing at a Glance

Induction (paralyzing for intubation): ~1.0 to 1.5 milligrams per kilogram (mg/kg) · Route: Intravenous (IV) or Intramuscular (IM) · Onset: ~30 to 60 seconds · Single-dose duration: ~5 to 10 min

Anesthetic Practice

Clinical Application

Succinylcholine is deployed almost exclusively for short, high-stakes scenarios. Its main appeal is that it acts incredibly fast to secure a dangerous airway and wears off quickly enough to recover a patient if breathing interventions fail.

Rapid Sequence Induction (RSI): When a patient has a full stomach, there is a nearly 100 percent risk of them vomiting and inhaling stomach acid into their lungs once they lose consciousness. Succinylcholine paralyzes the airway in under 60 seconds, allowing the provider to secure the breathing tube safely before vomiting can occur.
Electroconvulsive Therapy (ECT): Used in tiny doses to prevent psychiatric patients from breaking their own bones during medically induced seizures.
Treating Laryngospasm: When the vocal cords violently cramp shut and block airflow, a small dose will instantly relax the cords and reopen the airway.

Body-Wide Effects

Cardiovascular (Heart and Blood Vessels): It can dramatically slow the heart, a condition known as severe bradycardia. This happens because it confusingly stimulates the vagus nerve. This effect is especially pronounced in children and when a second dose is given too closely to the first.
Respiratory (Breathing): Causes complete paralysis of the diaphragm. The patient experiences total apnea, meaning they cannot take a single breath on their own.
Central Nervous System (Brain and Spinal Cord): The drug cannot cross into the brain at all. This means there is zero amnesia and zero sedation. The patient remains 100 percent awake and able to feel pain if no other drugs are given.
Metabolic and Contraindications: Because the initial muscle firing forces potassium out of the cells, patients with massive burns, crush injuries, or spinal cord damage can experience a fatal potassium spike. It is also a primary trigger for Malignant Hyperthermia, a rare genetic disorder that causes a lethal body temperature spike.

Medicolegal

Litigation Themes

Because succinylcholine is utilized in high-stress emergencies and carries a narrow margin for error, it appears frequently in medical malpractice litigation. The cases tend to follow very predictable patterns tied directly to the pharmacology of the drug.

Awareness under paralysis: Because the drug works in under 60 seconds, an anesthesia provider might mistakenly push the paralytic before the sedative takes effect. If the sedative dose is too small or fails entirely, the patient is completely paralyzed but totally conscious. Plaintiffs describe this as a waking nightmare, and it is a leading cause of psychological trauma in surgical patients.
Failure to secure the airway: Succinylcholine is given to rapidly place a breathing tube. If the provider cannot physically get the tube in, the patient cannot breathe for the full 5 to 10 minute duration of the drug. Irreversible brain damage starts occurring within 3 to 4 minutes, meaning the provider must act flawlessly to push oxygen back into the lungs.
Undiagnosed muscular dystrophy: When this drug forces muscles to depolarize, it naturally leaks a tiny bit of potassium into the blood. However, in pediatric patients with undiagnosed Duchenne muscular dystrophy, the drug causes massive muscle breakdown. This leads to severe hyperkalemia, instantly stopping the heart.
Atypical pseudocholinesterase: About 1 in every 2,500 people has a genetic mutation where their blood enzyme does not break the drug down properly. Instead of lasting 10 minutes, the paralysis can last for 4 to 8 hours. Cases often scrutinize whether the medical team recognized the prolonged block and kept the patient safely sedated on a mechanical ventilator.

Best Practice

Because succinylcholine provides absolutely no sedation, standard medicolegal protection requires the anesthesia provider to successfully push the sleep-inducing drug first. The standardized rapid airway sequence can be achieved via precise timing of the sedative before the paralytic. A basic sequence error, injecting the paralyzing syringe before the sleep syringe, will result in an agonizing experience of suffocation for the fully conscious patient. This simple mechanical mistake easily generates a completely indefensible medical malpractice claim. This is why strict syringe labeling and verification protocols are critical.

References

Lee C. Succinylcholine: its past, present, and future. Anesthesiology. 2001;95(2):434-436.
Sluga M, Ummenhofer W, Studer W, Siegemund M, Buser P. Duration of action of succinylcholine in patients with severe sepsis. Anesthesia & Analgesia. 2005;101(4):1142-1145.
Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology. 2006;104(1):158-169.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet Journal of Rare Diseases. 2007;2(1):21.
Domino KB, Posner KL, Caplan RA, Cheney FW. Awareness during anesthesia: a closed claims analysis. Anesthesiology. 1999;90(4):1053-1061.